Thursday, October 27, 2016 4:31:03 PM
That trading algorithms dominate trading is not news. It's estimated that about 75% of the volume done is automated trading. This includes high frequency trading but also includes many slower moving strategies. Some are based on predictive models but most are playing the bid-asked spread. The latter category is nothing more than automated market-making. This is especially true in lightly traded small and micro-cap stocks. As long as the spread is wide enough and there is enough activity from other sources the algo traders quietly crank out consistent but small returns on capital. The returns are so consistent that many of them operate largely with borrowed capital.
The one crucial ingredient for this business model to work there being sufficient interest in the stock from non-algo traders ( people). It's a low margin business and it needs volume. When trader/investor involvment drops below a certain level the algos can't make a go of it and look elsewhere. I believe this is now occurring in NNVC. I estimate the minimum daily volume required to keep the algos involved in NNVC, given its bid-asked spread is around 100,000 shares. A single day below that level will not be enough to drive the machines away but consistently low volume will and it becomes a self-reinforcing process.
The danger is important news in the face of low liquidity can cause large price swings, up or down. I assume NNVC is aware of this. This may be a factor in NNVC management being reluctant to let it all hang out.
Trendliner
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM